CINECA IRIS Institutional Research Information System

ANTONIOTTI, CARLOTTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.710
AS - Asia 4.734
EU - Europa 2.829
SA - Sud America 885
Continente sconosciuto - Info sul continente non disponibili 331
AF - Africa 212
OC - Oceania 10
Totale 18.711
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.414
SG - Singapore 1.678
CN - Cina 1.017
IT - Italia 966
HK - Hong Kong 863
BR - Brasile 700
VN - Vietnam 470
SE - Svezia 345
DE - Germania 311
BG - Bulgaria 228
GB - Regno Unito 208
FR - Francia 191
CA - Canada 170
IN - India 137
RU - Federazione Russa 122
JP - Giappone 121
FI - Finlandia 115
TR - Turchia 73
BD - Bangladesh 70
AT - Austria 66
AR - Argentina 62
CI - Costa d'Avorio 58
NL - Olanda 55
KR - Corea 54
MX - Messico 45
UA - Ucraina 44
IQ - Iraq 38
PL - Polonia 38
EC - Ecuador 33
ID - Indonesia 33
ZA - Sudafrica 31
ES - Italia 28
UZ - Uzbekistan 25
NG - Nigeria 24
SN - Senegal 24
PH - Filippine 22
SA - Arabia Saudita 22
VE - Venezuela 21
JM - Giamaica 20
PK - Pakistan 20
BE - Belgio 19
CO - Colombia 17
CZ - Repubblica Ceca 16
CR - Costa Rica 15
IE - Irlanda 15
PY - Paraguay 14
MA - Marocco 13
CL - Cile 12
EG - Egitto 12
PE - Perù 12
DZ - Algeria 11
TN - Tunisia 11
LT - Lituania 9
UY - Uruguay 9
IL - Israele 8
KE - Kenya 8
PT - Portogallo 8
AE - Emirati Arabi Uniti 7
CH - Svizzera 7
MY - Malesia 7
AZ - Azerbaigian 6
GT - Guatemala 6
JO - Giordania 6
NI - Nicaragua 6
NP - Nepal 6
NZ - Nuova Zelanda 6
OM - Oman 6
PA - Panama 6
RO - Romania 6
TH - Thailandia 6
TT - Trinidad e Tobago 6
TW - Taiwan 6
BO - Bolivia 5
BY - Bielorussia 5
NO - Norvegia 5
PR - Porto Rico 5
PS - Palestinian Territory 5
SY - Repubblica araba siriana 5
AO - Angola 4
AU - Australia 4
BB - Barbados 4
BS - Bahamas 4
ET - Etiopia 4
GR - Grecia 4
LB - Libano 4
XK - ???statistics.table.value.countryCode.XK??? 4
AL - Albania 3
DK - Danimarca 3
HN - Honduras 3
KH - Cambogia 3
LK - Sri Lanka 3
LY - Libia 3
RS - Serbia 3
AM - Armenia 2
BF - Burkina Faso 2
EU - Europa 2
HR - Croazia 2
KG - Kirghizistan 2
AI - Anguilla 1
BH - Bahrain 1
Totale 18.359
Salva come PNG Salva come JPEG
Città #
Ashburn 1.131
Singapore 931
Hong Kong 839
Woodbridge 762
San Jose 616
Santa Clara 614
Fairfield 536
Dallas 485
Chandler 470
Houston 425
Ann Arbor 401
Seattle 260
Shanghai 244
New York 230
Sofia 228
Wilmington 212
Cambridge 191
Beijing 186
Council Bluffs 173
Los Angeles 167
Boardman 154
Ho Chi Minh City 129
Milan 121
Princeton 113
Pisa 104
Lawrence 103
Tokyo 99
Lauterbourg 92
Medford 86
Florence 83
Hanoi 83
Hefei 81
London 79
Ottawa 74
Des Moines 69
São Paulo 69
Munich 68
Buffalo 62
Columbus 61
Abidjan 58
Vienna 56
Dearborn 50
Rome 49
Seoul 49
Frankfurt am Main 47
Düsseldorf 44
Cascina 41
Dong Ket 41
Redondo Beach 40
Helsinki 39
Ogden 39
San Diego 39
Istanbul 38
Chicago 34
Nanjing 34
Warsaw 33
Bremen 32
Genoa 31
Turin 31
Phoenix 30
Montreal 27
Turku 27
Toronto 26
Atlanta 25
Dakar 24
Lagos 23
Rio de Janeiro 23
Nuremberg 22
Orem 22
Redwood City 22
Serra 22
Mumbai 20
Washington 20
Boulder 19
Haiphong 19
Brussels 18
Tashkent 18
Jacksonville 17
Kunming 17
Fuzhou 16
San Francisco 16
Baghdad 15
Da Nang 15
Guangzhou 15
Chennai 14
Dhaka 14
Izmir 14
Manchester 14
Pune 14
Seacroft 14
Shenyang 14
Dublin 13
Brooklyn 12
Guayaquil 12
Nanchang 12
Boston 11
Brasília 11
Denver 11
Johannesburg 11
Marseille 11
Totale 12.376
Salva come PNG Salva come JPEG
Nome #
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study 403
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 252
Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial. 230
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 224
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO 202
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 200
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 200
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 200
TAS-102 for the treatment of metastatic colorectal cancer 193
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 188
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability 187
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 186
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 185
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 184
ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer 180
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 178
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 176
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 176
Circulating tumor DNA analysis in colorectal cancer: From dream to reality 176
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. 175
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients 174
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 174
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 173
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 173
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 170
Case-report: folfoxiri plus bevacizumab in "poor-risk" liver-only metastatic colorectal cancer: case report and state-of-the-art. 170
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 170
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 168
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 164
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib 164
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer 163
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 162
KRAS and BRAF genotyping of synchronous colorectal carcinomas. 161
First-line therapy for mCRC-the influence of primary tumour location on the therapeutic algorithm 161
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study 161
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 160
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. 160
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients 160
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials 158
Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). 157
Risk for developing brain metastases from colorectal cancer in long-term survivors with lung metastases and KRAS mutations. 156
CK7 and consensus molecular subtypes as major prognosticators in V600E BRAF mutated metastatic colorectal cancer 155
A still missing piece of the FIRE-3 puzzle 154
Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization 149
Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous histology. 148
Folfoxiri plus bevacizumab as first-line treatment in braf mutant metastatic colorectal cancer. 148
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features 148
KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab. 147
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab 147
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer 146
A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO). 146
Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer 145
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials 143
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 142
Folfoxiri plus Bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients. 141
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 141
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program 141
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 139
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 138
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis 137
Primary tumor location is a major independent prognostic factor for mcrc patients. 136
Prospective evaluation of candidate snps of vegf/vegfr pathway in metastatic colorectal cancer patients treated with first-line folfiri plus bevacizumab (BV). 136
Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV). 136
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. 135
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 135
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 135
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study 135
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 134
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm 134
prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. 134
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 133
FDG-PET/CT (PET) in the early prediction of benefit from first-line chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer (mCRC). 132
Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm 131
Detection of BRAF and KRAS mutations in DNA released by tumors in peripheral blood by an advanced digital droplet PCR. 131
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence 130
FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients. 130
Ksr1 gene polymorphism in mcrc patients treated with first-line folfiri and bevacizumab. 129
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study 128
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies 128
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib 128
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 128
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis 127
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Traslational analyses from the phase III BEBYP trial. 125
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis 125
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients? 124
Prospective study of EGFR intron 1 CA tandem repeats to predict factor benefit from cetuximab and irinotecan. 122
Impact of baseline gadoxetic acid-enhanced liver magnetic resonance and diffusion-weighted imaging in resectable colorectal liver metastases: A prospective, monocentric study 121
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study 121
KSR1 gene polymorphism in MCRC patients treated with first-line folfiri and bevacizumab. 118
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest 118
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer 118
Upfront chemotherapy regimens in unresectable disease: one, two, or three cytotoxics? 116
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials 114
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study 114
A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer 112
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study 112
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. 112
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study 112
null 111
The winding roadmap of biomarkers toward clinic: Lessons from predictors of resistance to anti-EGFRs in metastatic colorectal cancer 108
Totale 15.317
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.899
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.899
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022923 0 0 23 18 162 171 18 32 54 72 72 301
2022/20231.422 170 193 88 126 138 200 15 86 235 23 131 17
2023/20241.193 75 96 202 81 146 178 98 45 27 39 85 121
2024/20254.248 86 139 70 179 397 488 320 193 422 504 427 1.023
2025/20265.509 372 623 587 543 514 431 736 361 366 502 310 164
2026/20271.375 295 611 469 0 0 0 0 0 0 0 0 0
Totale 18.711